D. Boral Capital Analyst Recommendations & Stock Picks

Name: Community Performance Rating
Item: D. Boral Capital
Rating: 2.5
Author: MarketBeat

View the latest stock recommendations issued by analysts at D. Boral Capital. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from D. Boral Capital's equity research team. MarketBeat is not affiliated with or endorsed by D. Boral Capital.

2 Analysts
Updated 5/13/2026

Brokerage Ranking: Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Total Ratings: 498 Last 12 Months
Buy Ratings: 478 Last 12 Months
Sell Ratings: 0 Last 12 Months
Companies Covered: 64 Last 12 Months

Company	Current Price	Report Date	Analyst	Action	Price Target	Rating	Details
IBRX ImmunityBio	$7.22 -6.7%	5/5/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$23.00	Buy	View details for D. Boral Capital rating of ImmunityBio (NASDAQ:IBRX) on 5/5/2026
NRXP NRx Pharmaceuticals	$3.22 +5.2%	5/5/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$34.00	Buy	View details for D. Boral Capital rating of NRx Pharmaceuticals (NASDAQ:NRXP) on 5/5/2026
CLNN Clene	$6.70 -1.6%	5/4/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$23.00	Buy	View details for D. Boral Capital rating of Clene (NASDAQ:CLNN) on 5/4/2026
LCTX Lineage Cell Therapeutics	$1.30 -1.5%	5/4/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$3.00	Buy	View details for D. Boral Capital rating of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) on 5/4/2026
MNOV MediciNova	$1.40 +2.2%	5/4/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$9.00	Buy	View details for D. Boral Capital rating of MediciNova (NASDAQ:MNOV) on 5/4/2026
PRLD Prelude Therapeutics	$4.27 -1.4%	5/4/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$9.00	Buy	View details for D. Boral Capital rating of Prelude Therapeutics (NASDAQ:PRLD) on 5/4/2026
FATN Fatpipe Inc/UT	$3.78 -0.3%	5/1/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$8.00	Buy	View details for D. Boral Capital rating of Fatpipe Inc/UT (NASDAQ:FATN) on 5/1/2026
LUNG Pulmonx	$1.55 +0.6%	4/30/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$14.00	Buy	View details for D. Boral Capital rating of Pulmonx (NASDAQ:LUNG) on 4/30/2026
OSTX OS Therapies	$1.73 -4.9%	4/30/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$20.00	Buy	View details for D. Boral Capital rating of OS Therapies (NYSEAMERICAN:OSTX) on 4/30/2026
BMEA Biomea Fusion	$1.42 +3.6%	4/28/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$12.00	Buy	View details for D. Boral Capital rating of Biomea Fusion (NASDAQ:BMEA) on 4/28/2026
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
HUMA Humacyte	$1.05 +2.9%	4/28/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$25.00	Buy	View details for D. Boral Capital rating of Humacyte (NASDAQ:HUMA) on 4/28/2026
CMPX Compass Therapeutics	$2.07 +7.3%	4/27/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$30.00	Buy	View details for D. Boral Capital rating of Compass Therapeutics (NASDAQ:CMPX) on 4/27/2026
CRMD CorMedix	$7.98 -1.0%	4/27/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$14.00	Buy	View details for D. Boral Capital rating of CorMedix (NASDAQ:CRMD) on 4/27/2026
CRVO CervoMed	$3.06 -1.0%	4/22/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$31.00	Buy	View details for D. Boral Capital rating of CervoMed (NASDAQ:CRVO) on 4/22/2026
HUMA Humacyte	$1.05 +2.9%	4/21/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$25.00	Buy	View details for D. Boral Capital rating of Humacyte (NASDAQ:HUMA) on 4/21/2026
IBRX ImmunityBio	$7.22 -6.7%	4/21/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$23.00	Buy	View details for D. Boral Capital rating of ImmunityBio (NASDAQ:IBRX) on 4/21/2026
OMER Omeros	$11.46 -4.2%	4/21/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$36.00	Buy	View details for D. Boral Capital rating of Omeros (NASDAQ:OMER) on 4/21/2026
BEAT HeartBeam	$0.88 -4.6%	4/20/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade		Buy ➝ Hold	View details for D. Boral Capital rating of HeartBeam (NASDAQ:BEAT) on 4/20/2026
MDCX Medicus Pharma	$0.30 +4.9%	4/20/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$9.00	Buy	View details for D. Boral Capital rating of Medicus Pharma (NASDAQ:MDCX) on 4/20/2026
NNOX Nano-X Imaging	$1.84 -3.7%	4/20/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$5.00	Buy	View details for D. Boral Capital rating of Nano-X Imaging (NASDAQ:NNOX) on 4/20/2026
NRXP NRx Pharmaceuticals	$3.22 +5.2%	4/20/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$34.00	Buy	View details for D. Boral Capital rating of NRx Pharmaceuticals (NASDAQ:NRXP) on 4/20/2026
VNRX VolitionRX	$3.13 +15.9%	4/20/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy ➝ Hold	View details for D. Boral Capital rating of VolitionRX (NYSEAMERICAN:VNRX) on 4/20/2026
TRVI Trevi Therapeutics	$14.13 -0.2%	4/17/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$19.00	Buy	View details for D. Boral Capital rating of Trevi Therapeutics (NASDAQ:TRVI) on 4/17/2026
EVTL Vertical Aerospace	$2.63 +0.7%	4/16/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$12.00	Buy	View details for D. Boral Capital rating of Vertical Aerospace (NYSE:EVTL) on 4/16/2026
GOVX GeoVax Labs	$3.64 +32.4%	4/16/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Hold	View details for D. Boral Capital rating of GeoVax Labs (NASDAQ:GOVX) on 4/16/2026
IMUX Immunic	$13.05 +6.1%	4/15/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade		Buy ➝ Hold	View details for D. Boral Capital rating of Immunic (NASDAQ:IMUX) on 4/15/2026
VERI Veritone	$2.14 -6.1%	4/15/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$8.00	Buy	View details for D. Boral Capital rating of Veritone (NASDAQ:VERI) on 4/15/2026
HOVR New Horizon Aircraft	$3.14 +26.6%	4/14/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$11.00	Buy	View details for D. Boral Capital rating of New Horizon Aircraft (NASDAQ:HOVR) on 4/14/2026
NNOX Nano-X Imaging	$1.84 -3.7%	4/13/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$5.00	Buy	View details for D. Boral Capital rating of Nano-X Imaging (NASDAQ:NNOX) on 4/13/2026
ADUR Aduro Clean Technologies	$14.59 +2.2%	4/10/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$46.00	Buy	View details for D. Boral Capital rating of Aduro Clean Technologies (NASDAQ:ADUR) on 4/10/2026
COYA Coya Therapeutics	$4.81 -0.6%	4/10/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$15.00	Buy	View details for D. Boral Capital rating of Coya Therapeutics (NASDAQ:COYA) on 4/10/2026
ANIX Anixa Biosciences	$2.79 +1.5%	4/8/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$10.00	Buy	View details for D. Boral Capital rating of Anixa Biosciences (NASDAQ:ANIX) on 4/8/2026
BMEA Biomea Fusion	$1.42 +3.6%	4/8/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$12.00	Buy	View details for D. Boral Capital rating of Biomea Fusion (NASDAQ:BMEA) on 4/8/2026
CRVO CervoMed	$3.06 -1.0%	4/8/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$31.00	Buy	View details for D. Boral Capital rating of CervoMed (NASDAQ:CRVO) on 4/8/2026
IBRX ImmunityBio	$7.22 -6.7%	4/8/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$23.00	Buy	View details for D. Boral Capital rating of ImmunityBio (NASDAQ:IBRX) on 4/8/2026
NRSN NeuroSense Therapeutics	$0.82 +6.1%	4/8/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$14.00	Buy	View details for D. Boral Capital rating of NeuroSense Therapeutics (NASDAQ:NRSN) on 4/8/2026
OSTX OS Therapies	$1.73 -4.9%	4/8/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$20.00	Buy	View details for D. Boral Capital rating of OS Therapies (NYSEAMERICAN:OSTX) on 4/8/2026
RCEL Avita Medical	$4.58 +2.2%	4/8/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$10.00	Buy	View details for D. Boral Capital rating of Avita Medical (NASDAQ:RCEL) on 4/8/2026
ANIX Anixa Biosciences	$2.79 +1.5%	3/31/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$10.00	Buy	View details for D. Boral Capital rating of Anixa Biosciences (NASDAQ:ANIX) on 3/31/2026
AVXL Anavex Life Sciences	$2.69 -0.7%	3/31/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$24.00	Buy	View details for D. Boral Capital rating of Anavex Life Sciences (NASDAQ:AVXL) on 3/31/2026
Porter flew 3,300 miles to investigate this system (Ad) Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. Watch the full investigation and decide for yourself
EVTL Vertical Aerospace	$2.63 +0.7%	3/31/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$12.00	Buy	View details for D. Boral Capital rating of Vertical Aerospace (NYSE:EVTL) on 3/31/2026
PSTV Plus Therapeutics	$6.59 -4.4%	3/31/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy ➝ Hold	View details for D. Boral Capital rating of Plus Therapeutics (NASDAQ:PSTV) on 3/31/2026
URGN Urogen Pharma	$28.89 -3.3%	3/31/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$33.00	Buy	View details for D. Boral Capital rating of Urogen Pharma (NASDAQ:URGN) on 3/31/2026
BEAT HeartBeam	$0.88 -4.6%	3/27/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$5.00	Buy	View details for D. Boral Capital rating of HeartBeam (NASDAQ:BEAT) on 3/27/2026
HUMA Humacyte	$1.05 +2.9%	3/27/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$25.00	Buy	View details for D. Boral Capital rating of Humacyte (NASDAQ:HUMA) on 3/27/2026
OSTX OS Therapies	$1.73 -4.9%	3/27/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$20.00	Buy	View details for D. Boral Capital rating of OS Therapies (NYSEAMERICAN:OSTX) on 3/27/2026
VERI Veritone	$2.14 -6.1%	3/27/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$14.00	Buy	View details for D. Boral Capital rating of Veritone (NASDAQ:VERI) on 3/27/2026
CTSO Cytosorbents	$0.46 +0.2%	3/26/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$10.00	Buy	View details for D. Boral Capital rating of Cytosorbents (NASDAQ:CTSO) on 3/26/2026
VNRX VolitionRX	$3.13 +15.9%	3/26/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$60.00	Buy	View details for D. Boral Capital rating of VolitionRX (NYSEAMERICAN:VNRX) on 3/26/2026
BMEA Biomea Fusion	$1.42 +3.6%	3/25/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$12.00	Buy	View details for D. Boral Capital rating of Biomea Fusion (NASDAQ:BMEA) on 3/25/2026
HOTH Hoth Therapeutics	$0.69 +7.8%	3/25/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$5.00	Buy	View details for D. Boral Capital rating of Hoth Therapeutics (NASDAQ:HOTH) on 3/25/2026
NRSN NeuroSense Therapeutics	$0.82 +6.1%	3/25/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$14.00	Buy	View details for D. Boral Capital rating of NeuroSense Therapeutics (NASDAQ:NRSN) on 3/25/2026
CNTX Context Therapeutics	$2.60 +8.3%	3/24/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$9.00	Buy	View details for D. Boral Capital rating of Context Therapeutics (NASDAQ:CNTX) on 3/24/2026
EVTL Vertical Aerospace	$2.63 +0.7%	3/24/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$12.00	Buy	View details for D. Boral Capital rating of Vertical Aerospace (NYSE:EVTL) on 3/24/2026
NRXP NRx Pharmaceuticals	$3.22 +5.2%	3/24/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$34.00	Buy	View details for D. Boral Capital rating of NRx Pharmaceuticals (NASDAQ:NRXP) on 3/24/2026
TTRX Turn Therapeutics	$5.13 +3.2%	3/24/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$8.00	Buy	View details for D. Boral Capital rating of Turn Therapeutics (NASDAQ:TTRX) on 3/24/2026
AVXL Anavex Life Sciences	$2.69 -0.7%	3/23/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$24.00	Buy	View details for D. Boral Capital rating of Anavex Life Sciences (NASDAQ:AVXL) on 3/23/2026
FATN Fatpipe Inc/UT	$3.78 -0.3%	3/23/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$8.00	Buy	View details for D. Boral Capital rating of Fatpipe Inc/UT (NASDAQ:FATN) on 3/23/2026
IBRX ImmunityBio	$7.22 -6.7%	3/23/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$23.00	Buy	View details for D. Boral Capital rating of ImmunityBio (NASDAQ:IBRX) on 3/23/2026
MDCX Medicus Pharma	$0.30 +4.9%	3/19/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$27.00	Buy	View details for D. Boral Capital rating of Medicus Pharma (NASDAQ:MDCX) on 3/19/2026
PSTV Plus Therapeutics	$6.59 -4.4%	3/19/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$75.00	Buy	View details for D. Boral Capital rating of Plus Therapeutics (NASDAQ:PSTV) on 3/19/2026
TRVI Trevi Therapeutics	$14.13 -0.2%	3/18/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$19.00	Buy	View details for D. Boral Capital rating of Trevi Therapeutics (NASDAQ:TRVI) on 3/18/2026
VNRX VolitionRX	$3.13 +15.9%	3/18/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$60.00	Buy	View details for D. Boral Capital rating of VolitionRX (NYSEAMERICAN:VNRX) on 3/18/2026
HUMA Humacyte	$1.05 +2.9%	3/17/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$25.00	Buy	View details for D. Boral Capital rating of Humacyte (NASDAQ:HUMA) on 3/17/2026
IBRX ImmunityBio	$7.22 -6.7%	3/17/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$23.00	Buy	View details for D. Boral Capital rating of ImmunityBio (NASDAQ:IBRX) on 3/17/2026
NRSN NeuroSense Therapeutics	$0.82 +6.1%	3/17/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$14.00	Buy	View details for D. Boral Capital rating of NeuroSense Therapeutics (NASDAQ:NRSN) on 3/17/2026
VERI Veritone	$2.14 -6.1%	3/17/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$23.00	Buy	View details for D. Boral Capital rating of Veritone (NASDAQ:VERI) on 3/17/2026
COYA Coya Therapeutics	$4.81 -0.6%	3/16/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$15.00	Buy	View details for D. Boral Capital rating of Coya Therapeutics (NASDAQ:COYA) on 3/16/2026
CRVO CervoMed	$3.06 -1.0%	3/16/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$31.00	Buy	View details for D. Boral Capital rating of CervoMed (NASDAQ:CRVO) on 3/16/2026
NRXP NRx Pharmaceuticals	$3.22 +5.2%	3/16/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$34.00	Buy	View details for D. Boral Capital rating of NRx Pharmaceuticals (NASDAQ:NRXP) on 3/16/2026
CLNN Clene	$6.70 -1.6%	3/12/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$23.00	Buy	View details for D. Boral Capital rating of Clene (NASDAQ:CLNN) on 3/12/2026
CTXR Citius Pharmaceuticals	$0.70 +4.2%	3/11/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$6.00	Buy	View details for D. Boral Capital rating of Citius Pharmaceuticals (NASDAQ:CTXR) on 3/11/2026
USEG U.S. Energy	$0.97 +10.3%	3/10/2026	Jesse Sobelson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$3.50	Buy	View details for D. Boral Capital rating of U.S. Energy (NASDAQ:USEG) on 3/10/2026
ADUR Aduro Clean Technologies	$14.59 +2.2%	3/9/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$46.00	Buy	View details for D. Boral Capital rating of Aduro Clean Technologies (NASDAQ:ADUR) on 3/9/2026
IBRX ImmunityBio	$7.22 -6.7%	3/9/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$23.00	Buy	View details for D. Boral Capital rating of ImmunityBio (NASDAQ:IBRX) on 3/9/2026
MDCX Medicus Pharma	$0.30 +4.9%	3/9/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$27.00	Buy	View details for D. Boral Capital rating of Medicus Pharma (NASDAQ:MDCX) on 3/9/2026
NRSN NeuroSense Therapeutics	$0.82 +6.1%	3/9/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$14.00	Buy	View details for D. Boral Capital rating of NeuroSense Therapeutics (NASDAQ:NRSN) on 3/9/2026
NRXP NRx Pharmaceuticals	$3.22 +5.2%	3/9/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$34.00	Buy	View details for D. Boral Capital rating of NRx Pharmaceuticals (NASDAQ:NRXP) on 3/9/2026
OSTX OS Therapies	$1.73 -4.9%	3/9/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$20.00	Buy	View details for D. Boral Capital rating of OS Therapies (NYSEAMERICAN:OSTX) on 3/9/2026
TRVI Trevi Therapeutics	$14.13 -0.2%	3/9/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$19.00	Buy	View details for D. Boral Capital rating of Trevi Therapeutics (NASDAQ:TRVI) on 3/9/2026
LCTX Lineage Cell Therapeutics	$1.30 -1.5%	3/6/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Price Target	$2.00 ➝ $3.00	Buy	View details for D. Boral Capital rating of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) on 3/6/2026
LUNG Pulmonx	$1.55 +0.6%	3/5/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$14.00	Buy	View details for D. Boral Capital rating of Pulmonx (NASDAQ:LUNG) on 3/5/2026
MVIS Microvision	$0.62 +3.7%	3/5/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade		Buy ➝ Hold	View details for D. Boral Capital rating of Microvision (NASDAQ:MVIS) on 3/5/2026
CRVO CervoMed	$3.06 -1.0%	3/4/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$31.00	Buy	View details for D. Boral Capital rating of CervoMed (NASDAQ:CRVO) on 3/4/2026
HOTH Hoth Therapeutics	$0.69 +7.8%	3/4/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$5.00	Buy	View details for D. Boral Capital rating of Hoth Therapeutics (NASDAQ:HOTH) on 3/4/2026
TVGN Tevogen Bio	$9.61 -16.9%	3/4/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade		Buy ➝ Hold	View details for D. Boral Capital rating of Tevogen Bio (NASDAQ:TVGN) on 3/4/2026
NNOX Nano-X Imaging	$1.84 -3.7%	3/3/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$5.00	Buy	View details for D. Boral Capital rating of Nano-X Imaging (NASDAQ:NNOX) on 3/3/2026
TVGN Tevogen Bio	$9.61 -16.9%	3/3/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Price Target	$250.00 ➝ $100.00	Buy	View details for D. Boral Capital rating of Tevogen Bio (NASDAQ:TVGN) on 3/3/2026
VERI Veritone	$2.14 -6.1%	3/3/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$23.00	Buy	View details for D. Boral Capital rating of Veritone (NASDAQ:VERI) on 3/3/2026
URGN Urogen Pharma	$28.89 -3.3%	3/2/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$33.00	Buy	View details for D. Boral Capital rating of Urogen Pharma (NASDAQ:URGN) on 3/2/2026
One page of the SpaceX S-1 will move this stock overnight (Ad) When SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including power consumption for 1 million GPUs, a cost that rivals entire cities. That disclosure will name the supplier. One small, publicly traded power infrastructure company sits at the center of this - carrying a $1.5 billion backlog and priced like a utility. Dylan Jovine has the full breakdown. See the stock the S-1 revealed >>
IBRX ImmunityBio	$7.22 -6.7%	2/23/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$23.00	Buy	View details for D. Boral Capital rating of ImmunityBio (NASDAQ:IBRX) on 2/23/2026
LUNG Pulmonx	$1.55 +0.6%	2/20/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$14.00	Buy	View details for D. Boral Capital rating of Pulmonx (NASDAQ:LUNG) on 2/20/2026
GOVX GeoVax Labs	$3.64 +32.4%	2/19/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy ➝ Hold	View details for D. Boral Capital rating of GeoVax Labs (NASDAQ:GOVX) on 2/19/2026
HUMA Humacyte	$1.05 +2.9%	2/19/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$25.00	Buy	View details for D. Boral Capital rating of Humacyte (NASDAQ:HUMA) on 2/19/2026
COYA Coya Therapeutics	$4.81 -0.6%	2/18/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$15.00	Buy	View details for D. Boral Capital rating of Coya Therapeutics (NASDAQ:COYA) on 2/18/2026
CRVO CervoMed	$3.06 -1.0%	2/18/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$31.00	Buy	View details for D. Boral Capital rating of CervoMed (NASDAQ:CRVO) on 2/18/2026
IBRX ImmunityBio	$7.22 -6.7%	2/17/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$24.00	Buy	View details for D. Boral Capital rating of ImmunityBio (NASDAQ:IBRX) on 2/17/2026
NRXP NRx Pharmaceuticals	$3.22 +5.2%	2/17/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$34.00	Buy	View details for D. Boral Capital rating of NRx Pharmaceuticals (NASDAQ:NRXP) on 2/17/2026
RCEL Avita Medical	$4.58 +2.2%	2/17/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$10.00	Buy	View details for D. Boral Capital rating of Avita Medical (NASDAQ:RCEL) on 2/17/2026
IMUX Immunic	$13.05 +6.1%	2/13/2026	Jason Kolbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Price Target	$80.00 ➝ $40.00	Buy	View details for D. Boral Capital rating of Immunic (NASDAQ:IMUX) on 2/13/2026

MarketBeat Community Rating for D. Boral Capital

MarketBeat's community ratings are surveys of what our community members think about D. Boral Capital and other research firms in the last 90 days. Vote "Outperform" if you believe D. Boral Capital's recommendations will outperform the broader market over the long term. Vote "Underperform" if you believe D. Boral Capital's recommendations will underperform the broader market over the long term. You may vote once every thirty days.

Log in to vote on this brokerage.

COMMUNITY RATINGS: 2.5out of 5 (last 90 days)
2.5 of 5 stars
OUTPERFORM VOTES: 29 Believe will outperform the market
UNDERPERFORM VOTES: 28 Believe will underperform the market

Analysts at D. Boral Capital

D. Boral Capital's equity research team has issued ratings on 64 companies across 9 sectors over the past 12 months, covered by 2 analysts. The D. Boral Capital analysts below are listed by number of ratings issued in the last year.

D. Boral Capital Stock Coverage by Sector

D. Boral Capital concentrates its research most heavily in Medical (71.9%), Energy (6.3%) and Business Services (4.7%). The chart below shows how D. Boral Capital's 64 rated companies are distributed across all 9 sectors it covers.

Medical
46 companies
71.9%
Energy
4 companies
6.3%
Business Services
3 companies
4.7%
Computer and Technology
3 companies
4.7%
Aerospace
2 companies
3.1%
Basic Materials
2 companies
3.1%
Manufacturing
2 companies
3.1%
Finance
1 company
1.6%
Services
1 company
1.6%

Best & Worst Calls

Best Call
0000.0%
NASDAQ:IVVD
Reiterated Rating • Jan 10, 2025
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
NASDAQ:CERO
Initiated Coverage • Apr 22, 2025
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Similarly Rated Firms

D. Boral Capital - Frequently Asked Questions

D. Boral Capital's analysts currently have buy-equivalent ratings on 64 companies. Recent upgrades to buy include Can-Fite BioPharma.

D. Boral Capital's highest-rated analysts by MarketBeat's accuracy score include Jesse Sobelson and Jason Kolbert. Rankings are based on historical rating accuracy and price target precision over the past 12 months. MarketBeat tracks 2 analysts at D. Boral Capital.

D. Boral Capital has the deepest coverage in Medical (71.9% of rated companies), Energy (6.3% of rated companies), Computer and Technology (4.7% of rated companies), Business Services (4.7% of rated companies) and Basic Materials (3.1% of rated companies).

D. Boral Capital issued 498 ratings over the last 12 months across 64 companies â€” an average of roughly 42 rating actions per month. These include boost price target, downgrade, initiated coverage, lower price target, reiterated rating and upgrade. MarketBeat tracks every rating change as it's published so you can see the most current D. Boral Capital analyst actions.

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?